Dr Reddy’s Revises Wockhardt Terms In Light Of COVID-19 Slump
Deal Restructured After Wockhardt Unit’s Sales Fall In March And April
• By David Wallace
Generate a summary of this article
Listen to this article
Dr Reddy’s has completed its deal for Wockhardt’s branded generics business. However, the two companies have renegotiated the financial terms of the deal following the impact of the COVID-19 pandemic on Wockhardt’s business.
Dr Reddy’s And Wockhardt Have Renegotiated Their Deal • Source: Shutterstock
Dr Reddy’s and Wockhardt have renegotiated the terms of a deal that the pair have just completed, through which Dr Reddy’s will take ownership of Wockhardt’s branded generics business.
The pair had first announced the deal for Wockhardt to divest parts of its branded generics business in India and...
Stay ahead of every shift in generics and biosimilars.
Generics Bulletin brings you the latest updates that matter for the off-patent industry.
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.